What is Bafna Pharmaceuticals Ltd (BAFNAPH) share price return in the past 10 years?

Bafna Pharmaceuticals Ltd share price has appreciated 18.5% annually (CAGR) over the past ten years.

What is the share price of Bafna Pharmaceuticals Ltd (BAFNAPH)?

Company share prices are keep on changing according to the market conditions. The current trading price of Bafna Pharmaceuticals Ltd (BAFNAPH) on 04-Jun-2026 16:59:59 at 16:59 is 162.50.

What is the P/E ratio of Bafna Pharmaceuticals?

The latest standalone P/E ratio of Bafna Pharmaceuticals as of 04-Jun-2026 is 34.63.

What is the P/B ratio of Bafna Pharmaceuticals Ltd (BAFNAPH)?

The latest standalone P/B ratio of Bafna Pharmaceuticals Ltd (BAFNAPH) as of 04-Jun-2026 is 4.00.

What is the 52-week high and low of Bafna Pharmaceuticals Ltd (BAFNAPH)?

The 52-week high of Bafna Pharmaceuticals Ltd (BAFNAPH) is Rs. 204.95 and the 52-week low is Rs. 72.25.

Bafna Pharmaceuticals Ltd (BAFNAPH) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Bafna Pharmaceuticals Ltd (BAFNAPH)
Brand: Bafna Pharmaceuticals

Key Metrics

Valuation Multiples

Market Cap

₹384 Cr.

Current Price

₹162.5

52-Week Low / High

₹72 / 205

TTM EPS

₹4.7

TTM Sales

₹151 Cr.

Book Value per Share

₹40.6

P/E Ratio

34.63

Lower than its 5-year historical median

Industry PE

46.5

Price to Book (P/B)

4.00

Higher than its 5-year historical median

Price to Sales (P/S)

2.55

Higher than its 5-year historical median

EV/EBITDA

20.28

Higher than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

5.01%

Underperforms industry median

Return on Capital Employed (ROCE)

6.31%

Underperforms industry median

Return on Assets (ROA)

2.76%

Operating Profit Margin

7.5%

Net Profit Margin

2.85%

Gross Profit Margin

7.7%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

-4.34%

Operating Profit Growth (1 Year)

Improving versus 3-year growth rate

-2.07%

Net Profit Growth (1 Year)

Slowing versus 3-year growth rate

-43.54%

Asset Quality

Promoter Holding

75.00%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹72 Cr.

Equity

₹23.7 Cr.

Face Value

₹10

All Time Low / High

₹4.65 / 204.95

Bafna Pharmaceuticals stock performance

Key Ratios

Check Before You Invest

Quality

Locked

Valuation

Locked

Price Trend

Locked

Q.1 Is Bafna Pharmaceuticals Ltd a good quality company?

Bafna Pharmaceuticals Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Bafna Pharmaceuticals Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Bafna Pharmaceuticals Ltd vs industry peers?

Bafna Pharmaceuticals Ltd revenue CAGR is 27.99%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Bafna Pharmaceuticals Ltd?

Promoters hold 75.00% of the Bafna Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Bafna Pharmaceuticals Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 16.5% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	-0%	-6%	-7%	-20.9%	-3%	10.6%	8.4%	16.1%	9.6%	6.3%	-
Value Creation Index ⓘ	-1.0	-1.4	-1.5	-2.5	NA	-0.2	-0.4	0.2	-0.3	-0.6	-
Growth Parameters ⓘ
Sales ⓘ	85.3	65	47.2	43.6	42.5	71.2	85.1	115	152	146	151
Sales YoY Gr.	-	-23.9%	-27.4%	-7.5%	-2.7%	67.7%	19.6%	35.5%	32.2%	-4.3%	-
Adj EPS ⓘ	-6.6	-10.1	-15.9	-8.3	-8.4	2.4	2.1	4.3	2.6	2	4.7
YoY Gr.	-	NA	NA	NA	NA	NA	-10.6%	102.4%	-39.1%	-24.7%	-
BVPS (₹) ⓘ	31.5	22	17.1	8.8	-18.6	24	26.2	31.1	34.2	35.9	40.6
Adj Net Profit ⓘ	-12.2	-18.8	-37.7	-19.7	-2	5.6	5	10.1	6.1	4.6	11
Cash Flow from Ops. ⓘ	-3	19.8	-7.1	-1.1	-34.3	-13.6	9.7	5	9.5	22.1	-
Debt/CF from Ops. ⓘ	-27.1	4.2	-6.6	-42.2	-0.1	-1	1.1	4.6	2.6	1.3	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	6.1%	28%	19.7%	-4.3%
Adj EPS ⓘ	NA	NA	-2.4%	-24.7%
BVPSⓘ	1.5%	NA	11%	4.9%
Share Price	18.5%	3.8%	9%	118.1%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	-18.7	-35.9	-88.2	-64.4	-5.5	10.3	8.4	14.9	8	5.6	12.3
Op. Profit Mgn % ⓘ	3.8	-8	-74.4	-29.8	3	14.5	14	13.6	7.3	7.5	10.6
Net Profit Mgn % ⓘ	-14.4	-28.9	-80	-45.2	-4.7	7.8	5.8	8.7	4	3.2	7.4
Debt to Equity ⓘ	1.4	2	1.2	2.2	-0.7	0.2	0.2	0.3	0.3	0.3	0.2
Working Cap Days ⓘ	490	603	721	682	459	193	212	208	208	220	99
Cash Conv. Cycle ⓘ	247	290	236	31	3	40	74	81	79	88	38

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	85	65	47	44	42	71	85	115	152	146
Operating Expenses ⓘ +	83	70	82	57	41	61	73	100	141	135
Manufacturing Costs	10	8	10	11	11	14	13	14	20	23
Material Costs	62	50	33	24	16	32	40	63	87	81
Employee Cost	6	7	7	9	10	12	15	16	19	21
Other Costs ⓘ	4	6	31	13	4	4	6	7	15	10
Operating Profit ⓘ	3	-5	-35	-13	1	10	12	16	11	11
Operating Profit Margin (%)	3.3%	-8.0%	-74.4%	-30.0%	2.9%	14.5%	14.0%	13.6%	7.3%	7.5%
Other Income ⓘ +	1	1	31	0	0	1	2	3	4	3
Exceptional Items ⓘ	0	0	0	0	0	0	-2	0	0	-2
Interest ⓘ	12	11	7	2	0	1	1	2	2	3
Depreciation ⓘ	4	4	4	3	3	4	5	5	5	5
Profit Before Tax ⓘ	-13	-19	-14	-18	-2	6	5	12	7	4
Tax ⓘ	-0	-1	2	2	0	0	0	0	0	0
Profit After Tax	-12	-18	-16	-20	-2	6	5	11	7	4
PAT Margin (%)	-14.3%	-28.4%	-34.9%	-45.2%	-4.4%	8.2%	6.1%	9.8%	4.8%	2.9%
Adjusted EPS (₹)	-6.5	-9.9	-7.0	-8.3	-7.9	2.5	2.2	4.8	3.1	1.8
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Bafna Pharma - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	59	41	41	21	-4	57	62	73	81	85
Share Capital ⓘ	19	19	24	24	2	24	24	24	24	24
Reserves ⓘ	41	22	17	-3	-7	33	38	50	57	61
Debt +	80	82	47	46	3	13	10	20	21	23
Long Term Debt	35	39	23	23	3	3	5	8	11	14
Short Term Debt	45	43	23	23	0	10	5	12	10	9
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	30	23	28	39	13	11	12	28	35	31
Others Liabilities ⓘ	15	20	13	14	60	7	6	7	11	15
Total Liabilities ⓘ	185	167	128	121	71	86	90	130	148	153
Fixed Assets
Net Fixed Assets ⓘ +	47	43	40	37	35	36	39	40	40	59
Gross Block	72	72	73	73	74	80	88	95	99	106
Accumulated Depreciation	25	29	33	36	39	44	49	54	59	47
CWIP ⓘ	0	0	0	0	0	1	0	2	12	7
Investments ⓘ	18	18	1	1	0	0	0	0	0	0
Inventories	16	17	11	9	11	15	20	22	30	28
Trade Receivables	68	54	24	25	6	10	15	41	45	40
Cash Equivalents	3	3	3	3	8	2	0	8	1	3
Others Assets ⓘ	33	32	48	45	10	23	16	17	19	15
Total Assets ⓘ	185	167	128	121	71	86	90	130	148	153

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-3	20	-7	-1	-34	-14	10	5	9	22
PBT ⓘ	-13	-19	-14	-18	-2	6	5	12	7	4
Adjustment ⓘ	15	15	-20	5	-20	4	6	8	8	10
Changes in Working Capital ⓘ	-6	24	27	12	-12	-23	-1	-14	-5	8
Tax Paid ⓘ	0	0	0	0	0	0	-0	-0	-0	0
Cash Flow From Investing Activity ⓘ +	-1	-14	38	4	33	-5	-7	-7	-15	-21
Capex	-2	-0	47	-0	-1	-6	-8	-7	-15	-22
Net Investments	0	0	0	0	0	0	0	0	0	-0
Others ⓘ	1	-14	-9	4	34	1	1	-1	0	1
Cash Flow From Financing Activity ⓘ +	4	-5	-31	-2	7	12	-5	10	-1	1
Net Proceeds from Shares ⓘ	0	4	12	0	55	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	25	4	-16	-0	-20	3	-5	12	1	4
Interest Paid ⓘ	-12	-11	-7	-2	-0	-0	-0	-2	-2	-3
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-8	-2	-20	-0	-28	10	0	0	0	0
Net Cash Flow ⓘ	0	-0	0	-0	6	-7	-2	8	-6	2

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	-18.69	-37.05	-40.37	-64.36	N/A	22.26	8.79	16.75	9.52	5.01
ROCE (%)	-0.04	-5.98	-6.97	-20.9	N/A	10.62	8.42	16.12	9.56	6.31
Asset Turnover Ratio	0.47	0.38	0.32	0.35	0.44	0.9	0.96	1.05	1.1	0.97
PAT to CFO Conversion(x)	N/A	N/A	N/A	N/A	N/A	-2.33	2	0.45	1.29	5.5
Working Capital Days
Receivable Days	319.50	334.60	301.70	205.50	132.60	40	52.20	88.50	103.60	107.10
Inventory Days	66.90	91.10	106.10	83.50	88.90	68.80	76.60	67.20	62.10	72.20
Payable Days	191.30	196.50	280.40	512.60	586.40	133.60	105.60	118.30	134.40	149.70

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Bafna Pharmaceuticals Ltd FAQs

The current trading price of Bafna Pharma on 04-Jun-2026 16:59 is ₹162.5.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Bafna Pharma stood at ₹384.4 Cr

The latest P/E ratio of Bafna Pharma as of 03-Jun-2026 is 34.63.

The latest P/B ratio of Bafna Pharma as of 03-Jun-2026 is 4.00.

The 52-week high of Bafna Pharma is ₹204.9 and the 52-week low is ₹72.25.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bafna Pharma is ₹151 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Bafna Pharmaceuticals Ltd is a below average quality company.

The key valuation ratios of Bafna Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Bafna Pharmaceuticals Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals, incorporated in 1995, has been engaged in the manufacturing of pharmaceutical formulations for more than 3 decades. It exports its products to the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. It is known for providing consistent and unmatched service, supplying high-end pharmaceutical formulations to regulated and emerging markets. Additionally, the company has established itself as a competent player in the Contract Research and Manufacturing Services (CRAMS) industry. It has a WHO-GMP certified manufacturing facility. The facility is also accredited by EU GMP, UK MHRA, and TGA Australia for Non-Betalactum solid oral dosage forms.

The company has established an in-house state-of-the-art Quality Control Lab at the its manufacturing facility. The lab features sophisticated and cutting-edge technology with advanced instruments to ensure rigorous quality control across all manufacturing processes. The facility has a dedicated containment area for manufacturing high potent drugs within the current manufacturing facility. This includes special features for ensuring protection of workers from cytotoxic agents, specialized equipment for handling highly potent formulations, and protocols to achieve safety, quality control, and compliance with stringent regulations. The company holds active product registrations in multiple countries.

Business area of the company:

The company is engaged in the manufacturing of pharmaceutical products. It exports its products to the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries.

Product Range:

Anti-Diabetic
Cardiovascular
Anti-Hypertensive
Bi-Layer Antihypertensive

Awards, accreditations and recognition

1995: The company was awarded the WHO GMP.
2005: The company bagged the ‘Best Supplier Award’ from the State Pharmaceutical Corporation of Sri Lanka.
2009: The company received ISO 9001: 2000 Certificate of Registration for Manufacture and Export of Pharmaceutical products.
2010: The company received ‘Best Supplier Award’ from the Government of Sri Lanka, Gold Quality Excellence Award 2009.
2011: The company received Indian Drug Manufacturer's Association (IDMA) Quality Excellence Award 2010 - Silver Award under the category of Formulations Units.
2011: The company received Excellence Award 2011 from IES.
2011-12: The company received IDMA - Gold Award - Quality Excellence Award.
2012-13: Bafna received the Prestigious Certificate Of Excellence From 16th State Pharmaceuticals Corporation (spc) Suppliers Convention 2013, Sri Lanka.
2024-2025: Excellence in Pharma Exports by Times of India.
2024-2025: Top 10 Finished Dosage Formulations Manufacturer by India Pharma Outlook.
2024-2025: Emerging Company of the Year 2025 - Healthcare by MSME Chamber of Commerce & Industry of India.
2024-2025: MSME Best CEO 2025 by MSME Chamber of Commerce & Industry of India.

Bafna Pharmaceuticals Ltd (BAFNAPH)

Bafna Pharmaceuticals Ltd (BAFNAPH)

Bafna Pharmaceuticals stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Bafna Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Bafna Pharmaceuticals Ltd FAQs

About Bafna Pharmaceuticals Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Bafna Pharmaceuticals Ltd (BAFNAPH)

Bafna Pharmaceuticals Ltd (BAFNAPH)

Bafna Pharmaceuticals stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Bafna Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Bafna Pharmaceuticals Ltd FAQs

What is the share price of Bafna Pharma?

What is the market cap of Bafna Pharma?

What is the P/E ratio of Bafna Pharma?

What is the P/B ratio of Bafna Pharma?

What is the 52-week high and low of Bafna Pharma?

What is the TTM revenue of Bafna Pharma?

Is Bafna Pharmaceuticals Ltd a good quality company?

Is Bafna Pharmaceuticals Ltd undervalued or overvalued?

Is Bafna Pharmaceuticals Ltd a good buy now?

About Bafna Pharmaceuticals Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.